Info
caplacizumab
Among patients with TTP, treatment with caplacizumab was associated with faster normalization of the platelet count; a lower incidence of a composite of TTP-related death, recurrence of TTP, or a thromboembolic event during the treatment period; and a lower rate of recurrence of TTP during the trial than placebo.
Scully M, Cataland SR, Peyvandi F, et al. Caplacizumab Treatment for Acquired Thrombotic Thrombocytopenic Purpura. New England Journal of Medicine. 2019;380(4):335-346. doi:10.1056/nejmoa1806311
In this issue of Blood, Kühne et al present a retrospective cohort study demonstrating that a treatment regimen that omits therapeutic plasma exchange (TPE) and uses immunosuppression and upfront caplacizumab alone is safe and effective for patients with immune thrombotic thrombocytopenic purpura (iTTP) 省略治療性血漿置換(TPE) 並單獨使用免疫抑制和前期 caplacizumab 的治療方案對於免疫性血栓性血小板減少性紫斑( iTTP) 病人是安全有效的
Lee GM. iTTP loses TPE. Blood. 2024;144(14):1462-1463. doi:10.1182/blood.2024025574